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Abstract
Great progress has been made in the therapeutic strategies of multiple diseases that lack 
curative treatments with the transplantation of mesenchymal stem cells (MSC), such 
as in onco-hematological diseases, myocardial infarction (MI), cerebrovascular diseases, 
degenerative diseases of the nervous system (multiple sclerosis, Alzheimer’s disease), 
and diseases of the immune system, among others. Stem cells (SC) participate in the 
biological processes of tissue regeneration and repair through cell replication. Recently, 
the beneficial therapeutic effects of SCs that are generated by the release of proteins 
with paracrine actions and not by cell differentiation are more well known, and 80% of 
the therapeutic effect of SC is attributed to paracrine actions. The MSCs release large 
amounts of proteins and growth factors (GF), nucleic acids, proteasomes, exosomes, 
and microRNA, and membrane vesicles known as the secretome are released into the 
extracellular space, regulating multiple biological processes. Currently, the therapeutic 
strategies in tissue engineering (TE) and regenerative medicine (RM) are focused on 
the management of products derived from cells that act, both locally and remotely, 
in the affected tissue or organ, achieving regenerative actions. The application of new 
knowledge of the secretome initiates a change in the paradigm of regenerative therapy 
by knowing more about and using cell products derived from cells as a “factory” for 
biological drugs.
Keywords: stem cell, mesenchymal stem cells, cell therapy, paracrine activity, 
exosomes, extracellular vesicle, microvesicles, microRNA, miRNA, regenerative 
medicine, tissue engineering, growth factors, extra-cellular matrix, epidermal growth 
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1. Introduction
The mesenchymal stem cell (MSC) therapies offer new opportunities for confronting diseases 
that lack curative treatments through the properties of multipotentiality, self-renewal, and the 
secretion of paracrine factors derived from exosomes (cytokines, growth factors, microRNAs, 
and proteases), which act as mediators of intracellular communication and induce the repair 
and regeneration of organs and tissues [1].
Cell therapy with MSCs is safe and effective in the treatment of degenerative and traumatic 
diseases; they are found in vivo in minimal quantities throughout the body and they have the 
ability to differentiate into bone, cartilage, and adipose tissue through stimuli and in culture. 
The MSCs are located in the perivascular environment, activating and creating a regenerative 
microenvironment, with the secretion of molecules to regulate the immune response; how-
ever, the therapeutic effects through paracrine interactions of the MSCs are of short duration. 
The response to changes in the environment is attributed to MSCs through the transcriptional 
regulation of mediators that control inflammation, remodeling, repair, and cellular recruit-
ment. The repair process involves the regulation of extracellular matrix (ECM) deposition, 
collagen synthesis, fibroblast proliferation, platelet activation, fibrinolysis, and angiogenesis; 
the immune process suppresses T-cells, activates macrophages, and recruits neutrophils [2].
Cell differentiation and replacement is attributed to cellular secretions that function as therapeu-
tic inducers. The secretions of extracellular vesicles (EV) are both local and systemic. To deter-
mine the functions of the factors secreted by the MSCs in regeneration, it is necessary to identify 
precisely the molecular profile of the secretome of the MSC constituted by growth factors (GF), 
cytokines and chemokines, proteases, ECM, hormones, and lipid mediators, and so on [3].
The secretome of MSCs contains multiple overlapping elements that make it difficult to iden-
tify them. The in vivo examination of the secretome of MSCs and the strategies to modulate it 
and the result of the analysis are essential for the design of the next generation of regenerative 
therapies without cells. In this way, questions arise about the regulatory function of the sec-
retome of the MSC, such as (i) what are the most effective approaches to study the secretome 
both in vitro and in vivo and are new technologies necessary to achieve it? (ii) how do the 
properties of the secretome change or become manageable, and after the transplant how does 
it evolve in the local microenvironment? (iii) what are the best methods to achieve the sustain-
ability of the secretome and the control in the transplant? [4].
2. Stem cells and mesenchymal stem cells
More than 200 different types of cells make up embryonic and adult tissues and are regulated 
by local and systemic environmental factors. Embryonic stem cells (ESC) derived from the 
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internal cell mass of the blastocyst are constituted by ectoderm, endoderm, and mesoderm. 
Adult stem/progenitor cells, known as somatic SC, are undifferentiated cells located through-
out the body. These cells have a high proliferative capacity and a differentiation potential 
limited to their lineage; they participate in regeneration, cell turnover, and homeostasis. The 
main function during life is to maintain the number of differentiated cells at a constant level 
and to replace dead cells or cells lost due to injury or disease [5].
SCs have a great capacity for self-renewal and the potential to produce a differentiated prog-
eny. An SC can have the same phenotype but be less “mature” or less “differentiated” than its 
descendants and is classified into SCs/progenitors, “somatic”, “adult”, or “tissue” embryonic 
and nonembryonic cells. ESC are pluripotent, and most populations of progenitor cells arising 
during embryonic development cannot self-renovate and have common properties with adult 
SCs, such as the potential of differentiation and the capacity for asymmetric cell division [6].
SC can be differentiated into specific cell types. Their ability to self-renew is through indefinite 
replication, resulting in the creation of two identical SCs, and under appropriate conditions, 
differentiated into more specialized cells. The MSCs are spindle-shaped adherent plastic cells 
that can be isolated from the bone marrow (BM), adipose tissue, and other tissues; are multi-
potent; and have the ability to differentiate. In vitro they can differentiate into bone; a subset of 
the cells have a high proliferative potential colony-forming units (CFU-F) when they are grown 
in culture. Hematopoietic SCs regulate and maintain hematopoiesis in the microenvironment 
of BM [7].
The MSCs can produce blood cells, although they are derived from a different population called 
hematopoietic SCs. The MSCs are classified as nonhematopoietic multipotential SCs and have 
the ability to differentiate into mesenchymal as well as nonmesenchymal lineages. The MSCs 
have the capacity for self-renewal, colony formation, phenotypic expression pattern, and dif-
ferentiation potential; they interact with cells of the innate and adaptive immune system in the 
modulation of immune response. They participate in physiological processes, such as tissue 
homeostasis and hematopoiesis, and in pathological processes such as diseases of aging, tissue 
damage, and degenerative, inflammatory, and autoimmune diseases. After administration in 
vivo, MSCs induce tolerance and migrate to injured tissues where they inhibit the release of 
proinflammatory cytokines and promote the survival of damaged cells [8].
The International Society of Cell Therapy has established the following minimum criteria to 
define multipotent MSCs: first, they must be adherent to the plastic, under standard culture 
conditions (minimal essential medium, plus 20% fetal bovine serum). Second, MSCs should 
express CD105, CD73, and CD90 and should not express surface molecules such as CD45, 
CD34, CD14 or CD11b, CD79α or CD19, and HLA-DR. Third, they must be differentiated into 
osteoblasts, adipocytes, and chondroblasts in vitro. They can be isolated from many adult tis-
sues, BM, and adipose tissue. They have the ability to differentiate and trans-differentiate into 
cells of different lineages and immunomodulation capacity. The term “mesenchymal stem 
cell” is used to refer to the subset of mesenchymal cells that demonstrate SC activity and meet 
these criteria [9, 10].
The main characteristics of MSCs are the potential for self-renewal, differentiation, and mul-
tipotency. Under appropriate microenvironmental conditions, they can proliferate and give 
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rise to other types of cells, they can be trans-differentiated in cells of other lineages, and exert 
proregenerative, immunomodulatory, and antiinflammatory functions. Because of these 
characteristics, they can be an ideal therapeutic strategy for the treatment of inflammatory 
and systemic autoimmune diseases and are essential in the tissue regeneration of congenital, 
degenerative, and traumatic diseases [5].
The origin of MSCs in vivo is controversial. They are located in the perivascular area of the 
adventitia from almost all vessels (arteries and veins). They are pericytes, which are in inti-
mate contact with the basement membrane and the surrounding endothelial cells, forming 
the extensive network of the microvasculature. Phenotypic similarities are evident among 
microvessels, and pericytes can be isolated from any vascularized tissue, near smooth muscle 
cells of arterioles, venules, and larger vessels, and preserve the expression of pericyte markers 
such as NG2 and CD146 [11].
The immunomodulatory activity of MSCs is mediated by paracrine factors. Among these, 
the exosomes participate in the communication between the MSCs and the target tissue. To 
demonstrate this, one study investigated the effect of the exosomes derived from MSCs on 
peripheral blood mononuclear cells (PBMC), especially on T-cells. It was shown that the MSC-
derived exosomes extracted from the BM of healthy donors suppressed the secretion of the 
proinflammatory factor TNF-α and IL-1β and, conversely, increased the concentration of the 
antiinflammatory factor TGF-β in vitro. Exosomes can induce the conversion of T helper type 1 
(Th1) into T helper type 2 (Th2) cells and reduce the potential of the T-cells to differentiate into 
effector T-cells producing interleukin 17 (Th17). In addition, the levels of regulatory T-cells 
(Treg) and protein 4 associated with cytotoxic T lymphocytes were increased. The results 
suggest that the exosomes derived from MSCs possess immunomodulatory properties [12].
Inflammation is a response of the organism to self-evolutionary harmful stimuli to maintain 
homeostasis. In the process, MSCs secrete paracrine factors that influence immune cells, den-
dritic cells, and macrophages, polarizing them toward a tolerogenic phenotype. Regulatory 
immune cells accumulate and converge in their regulatory pathways and create a tolerogenic 
environment conducive to immunomodulation [13].
During tissue regeneration, the regulation of the inflammatory process is essential, as is the 
control of local and systemic inflammatory response without causing damage in the injured 
tissues. The MSCs possess immunomodulatory properties that facilitate the repair of tissues by 
releasing exosomes, which generate an appropriate microenvironment to modulate inflamma-
tion. The exosomes contain bioactive molecules, which act as a cell-cell communication vehicle 
and influence the activities of receptor cells. During this process, the horizontal transfer of exo-
somal microRNA to recipient cells regulates the expression of the target gene and is essential 
to control inflammation and tissue homeostasis to develop new therapeutic approaches [14].
In MSC therapy, the following points should be kept in mind: (i) arrival at sites of ischemia or 
injury, when administered systemically and (ii) modulation of the immune responses medi-
ated by T-cells, which express chemokine receptors and ligands in the migration of the cells 
and the homing process.
The MSCs induce immunomodulatory effects, interact with innate immune cells (dendritic cells, 
monocytes, natural killer [NK] cells, and neutrophils) and cells of the adaptive immune system 
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(Th1, cytotoxic T lymphocyte and B lymphocyte), secreting factors such as TGF-β, IL-10, IDO, 
PGE-2, sHLA-G5. The MSCs are considered immune privileged cells due to the low expression of 
the major histocompatibility complex class II (MHC-II) and expressing costimulatory molecules 
on the cell surface and interfering with different pathways of the immune response. In vitro, 
MSCs inhibit cell proliferation of T-cells, B-cells, NK cells, and dendritic cells (DC), producing 
what is known as “division arrest anergy”. On the other hand, MSCs can inhibit diverse key func-
tions of the immune cells, such as the secretion of cytokines and the cytotoxicity of T-cells and NK 
cells; B-cell maturation and antibody secretion; DC maturation and activation; as well as antigen 
presentation. In inflammation, MSCs must be activated to generate immunomodulation by sup-
pression of molecules such as tumor necrosis factor (TNF)-α and interferon (IFN)-γ. On the other 
hand, MSCs recruit regulatory T lymphocytes (Tregs) from both lymphoid and graft organs [15].
In vivo studies have shown differences with respect to the immunomodulatory properties 
of MSCs. Currently, the effectiveness of MSC treatment to suppress the abnormal immune 
response in scenarios such as prevention, treatment of allograft rejection periods, and autoim-
mune and inflammatory diseases is being investigated. Clinical trials in humans are being 
developed in the treatment of autoimmune diseases such as Crohn’s disease, ulcerative coli-
tis, multiple sclerosis, diabetes mellitus type 1, prevention of allograft rejection, survival of 
bone marrow and kidney grafts, and treatment of resistant graft versus host disease [16].
In vitro the MSCs are able to differentiate to osteogenic, chondrogenic, adipogenic, and myo-
genic lineages, and they express markers of pericytes (CD146+, CD34-, CD45-, CD56). In 
vascular damage, released pericytes become MSCs, are activated by the lesion, and respond 
by secreting bioactive molecules that inhibit immune cells that produce tissue damage and 
prevent the development of autoimmune reactions. The secretion of these bioactive molecules 
establishes a regenerative microenvironment in the injured tissue [17].
Activated MSCs also locally produce antimicrobial peptides such as LL37, which eliminate 
bacteria and attract macrophages and hematopoietic cells. Together, these function as thera-
peutic elements in the affected site and stimulate and increase TH2 and regulatory T-cells 
through inhibitory effects on the immune system. Thus, MSCs function as “medical signaling 
cells” with healing actions at sites of injury or inflammation. These trophic and immuno-
modulatory activities suggest that MSCs can serve as “pharmacies” regulated in situ. The 
MSCs act as “sentinels” in acute and chronic injuries; they function as multidrug dispensaries 
in situ, with “pharmacy” functions that promote natural regeneration [18].
In addition to the secretion of cytokines/chemokines, the MSCs show a great capacity for 
mitochondrial transfer and microvesicle secretion (exosomes) in response to injury. On the 
other hand, MSCs are recruited to the lesion to repair damaged tissues, an event intimately 
associated with tumorigenesis. Tumors are made up of different types of cancer cells that 
contribute to heterogeneity. Among these populations are the cancer stem cells (CSC) that 
participate in its onset and progression. A CSC population consists of MSCs that differ in 
cells with mesodermal characteristics. Resident or migratory MSCs favor angiogenesis and 
increase tumor aggressiveness. This interaction between MSCs and CSCs is fundamental in 
the development of carcinogenesis, progression, and metastasis. In cancer, tumor cells aber-
rantly secrete large amounts of exosomes to transport paracrine signals that contribute to 
tumor and distance interaction [19–21].
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The MSCs represent an opportunity in cell therapy because: (i) they are easily accessible; (ii) 
the isolation is simple, they can be expanded to clinical scales in a short period; (iii) they can 
be preserved with a minimum loss of potency and stored for administration; and (iv) so far 
they have not shown adverse reactions to allogeneic transplantation compared with auto-
transplantation, and they can expand in vitro, without altering their main properties.
3. Therapeutic approach
The control of the growth, division, and differentiation of MSCs in a safe and predictable 
manner is essential in tissue regeneration. They should be used as bioreactors to achieve spe-
cific cell types in conjunction with soluble factors that lead to healing. A therapeutic strategy 
is the transplantation of differentiated functional cells to replace cells lost or damaged by 
disease. However, the strategy requires regulation of the differentiation of the SC toward 
specific cellular destinations, including those that are outside the mesenchymal lineage, by 
means of trans-differentiation, where genetic manipulation can promote it and the expression 
of certain transcription factors for cellular reprogramming.
Because of the plasticity of MSCs, in addition to generating bone, adipose tissue, cartilage, and 
other skeletal structures, differentiation can generate lineages of liver, kidney, muscle, dermal, 
nerve, and cardiac cells; regenerate damaged tissue; and treat inflammation in the MI, brain, 
spinal cord, cartilage, and bone lesions, Crohn’s disease, graft-versus-host disease (GvHD) and 
BM transplantation. The mechanisms of orientation and immunomodulation, the potential for 
multiple differentiations, and paracrine actions contribute to tissue repair. Induced pluripotent 
stem cells (iPSC) are very promising for discovering new drugs in medicine regenerative (MR), 
for their ability to differentiate in any type of cell, and iPSC-induced technology will allow the 
development of new therapies based on cells and their products as new biological drugs [22].
Transcriptional and epigenetic regulations are essential mechanisms underlying pluripo-
tency, are studied in ESCs, allowing them to give rise to lineages of the three germ layers, and 
are used in basic studies of tissue formation that provided the foundation for regenerative 
therapy. Continuous self-renewal is an essential requirement to maintain the transcriptional 
profile and pluripotent state. To differentiate themselves in other cell lineages, ESCs need to 
change the transcriptional profiles. On the other hand, new regulators of pluripotency and 
gene expression may emerge with the study of miRNAs [23].
The immunomodulatory properties of MSCs are related to paracrine factors whose expression 
varies in each pathology. These factors have a direct impact on cells of the adaptive immune 
system such as T-cells. However, in the inflammatory process, MSCs secrete paracrine factors 
that influence other subpopulations of immune cells, such as dendritic cells and macrophages, 
and polarize them toward a tolerogenic phenotype. In vivo, these immunomodulatory fac-
tors are increased in the serum of animal models with inflammatory diseases treated with 
MSCs. The manipulation of immune regulatory cells could improve the immunomodulatory 
therapeutic strategies of MSCs. Regulatory immune cells accumulate and converge in their 
regulatory pathways to create a tolerogenic environment [24].
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The paracrine signals of the extracellular environment influence the microenvironment of 
MSCs, both in proliferation and in differentiation. Many therapeutic strategies try to increase 
the effectiveness of regenerative therapies by direct application in the affected tissue or by 
differentiation in mature tissues. The MSCs have phenotypic plasticity and harbor an arsenal 
of bioactive molecules that are released by detecting signals in the local environment or pack-
aging in EVs [25, 26].
The rigidity and/or topography of the cellular environment controls the differentiation of the 
MSCs, the physical signals determining the target, and cellular differentiation, an environ-
ment with high rigidity that leads to osteogenic differentiation, while low rigidity induces 
lipogenic differentiation. These effects are independent of the chemical/biochemical inducers. 
Physical factors, such as tension, produce a reorganization of the cytoskeleton during the 
differentiation of the MSCs and affect the expression of the essential gene of the process. 
Physical signals control the lineage specification of the MSCs, reorganizing and adjusting the 
cytoskeleton, and the cells perceive physical signals and transform these into biochemical and 
biological signals. Specifically, biophysical signals can initiate and strengthen biochemical 
signaling for the determination and differentiation of the destination of MSCs. The physical 
properties of the cell environment direct the structural adaptation and functional coupling of 
the cells to their environment [27].
To facilitate the identification of terms that we use in the following section, we present here 
abbreviations and meaning of the terms:
“Extracellular vesicle” (EV), is synonymous with “membrane vesicle” (suggested for all 
populations of vesicles derived from cells);
“Exosomes” are vesicles of 50–100 nm in diameter, generated by exocytosis of multivesicular 
bodies (MVB), and are a macromolecular complex involved in the degradation of RNA;
“Ectosoma” is a microvesicle derived from neutrophils or monocytes;
“Microparticle” (MV) is any small particle, regardless of its origin, and is more appropriate to 
indicate membrane-bound structures;
“Microvesicles” (ExMV) are larger extracellular membrane vesicles (100–1000 nm in diam-
eter) [28].
The EVs are classified into three main classes:
1. Microvesicles/microparticles/ectosomes: these are produced by the formation of buds and 
the fusion of the plasma membrane;
2. Exosomes: these form within the endosomal network and are released by fusing the mul-
tivesicular bodies with the plasma membrane; and
3. Apoptotic bodies: these are released as blisters of cells that undergo apoptosis.
The current nomenclature classifies the vesicles by their biogenesis. The criteria for classification 
are according to their origin, function, or biogenesis.
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4. Mesenchymal stem cell extracellular microvesicles (ExMV)
Organ regeneration technologies attempt to restore the anatomical structure and original 
functionality of a damaged organ. Usually, the response is fibrosis and scar tissue forma-
tion and no regeneration. The strategies of IT and MR for the repair of organs/tissues allow 
restoration of normal functioning. The development of new products, derived from MSCs 
considered as active biological elements, has already started.
The mechanisms of action of therapies with MSC have focused on paracrine actions, for the 
ability to generate regeneration without the application of cells. The primordial component, 
which creates a regenerative medium, is exosomes: intraluminal vesicles of 40–100 nm that 
transfer proteins and nucleic acids between cells and establish intracellular communication. 
The exosomes participate in organogenesis and regeneration and repeat the bioactivity of the 
SCs [29].
The extracellular space of multicellular organisms contains metabolites, ions, proteins, and 
polysaccharides. In the extracellular environment, a large number of mobile vesicles par-
ticipate, and the term “extracellular vesicles or EVs” is suggested, which includes exosomes, 
microvesicles, microparticles (MV) and apoptotic bodies. The EVs comprise a heterogeneous 
population of lipid vesicles derived from cells containing exosomes and microvesicles. They 
are the mediators of the intercellular information transfer and can be vehicles for the admin-
istration of drugs of autologous cellular products. The therapeutic effects of cell therapies are 
mainly attributed to the EVs secreted by cells and directly involved in tissue regeneration 
processes [30].
Currently, interest focuses on EVs (exosomes and MV). Vesicles similar to exosomes have a 
common origin; however, they lack lipid-based microdomains; their size and sedimentation 
properties distinguish them from exosomes; and the term refers to an extracellular vesicle 
with a diameter of 40–150 nm and a density of 1.09–1.18 g/ml, proteins, nucleic acids, and 
membrane vesicles that generate a regenerative environment [31, 32].
Eukaryotic cells communicate with each other through direct interaction (juxtacrine contact 
dependent signaling) or by the secretion of factors such as hormones, GF, and cytokines, 
when they act in the cell itself (autocrine signaling) or act in neighboring cells (paracrine 
signaling) and distant cells (endocrine signaling). Tissue regeneration is related to the release 
of paracrine and autocrine substances and not only by cellular replication and differentia-
tion. Eighty percent of the therapeutic effect of adult SCs is through paracrine actions. The 
molecules released by the SCs, the secretome, contain molecules (100), proteins, microRNA, 
GF, proteasomes, and exosomes, which generate paracrine activities. The composition of the 
different types of molecules depends on the stage and varies according to cell type, age, and 
environment. The secretory activity of cell-derived byproducts acts at a distance and is the 
main regenerative mechanism [33, 34].
In multicellular organisms, cells exchange information with signals from molecules in pack-
ages included in the EVs, which contain proteins, lipids, and nucleic acids. When released in 
the extracellular environment, exosomes interact with receptor cells by adhesion to the cell 
surface, by lipid-ligand receptor interactions, by endocytic uptake, or by direct fusion of the 
vesicles to the cell membrane [35].
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Preclinical and clinical studies with MSCs propose inducing endogenous repair, and this rep-
resents a new paradigm for the treatment of multiple diseases. The factors are produced from 
activated cells extracted from their physiological niches, aspirated BM or mobilized blood, 
such as peripheral blood mononuclear cells (PBMC), and these release biologically active 
paracrine factors that induce regeneration. The apoptotic secreted from PBMCs has been 
used successfully for the treatment of MI, chronic heart failure, spinal cord injury, stroke, and 
wound healing [36].
The EVs derived from the MSCs, exosomes, are powerful intercellular communication vehicles; 
composed of a lipid bilayer that contains transmembrane proteins, cytosolic proteins, and RNA; 
participate in diverse physiological and pathological functions of both receptor and parental 
cells; and transfer the information to other cells and influence the function of the recipient cell. 
The EVs transmit biomolecules (proteins, lipids, nucleic acids, and sugars) as a single information 
packet or deliver multiple messengers simultaneously to sites distant from the source EVs [37].
The EVs are between 100 and 1000 nm in diameter, and they are microvesicles, ectosomes, 
or microparticles, which sprout from the cellular plasma membrane. Other types of vesicles 
are exosomes, which are generated within multivesicular endosomes or multivesicular bod-
ies (MVBs), secreted by fusing with the plasma membrane.) Exosomes are vesicles that are 
enriched with components derived from endosomes. They are targeted to the recipient cells 
and, once bound to a target cell, the EVs induce signaling through the receptor-ligand interac-
tion or are internalized by endocytosis and/or phagocytosis, even fusing with the membrane 
of the target cell to release its cytosol content, which modifies the cellular receptor [38].
Exosomes of endocytic origin transmit different intercellular signals by surface interactions 
and by the displacement of functional RNA from one cell to another and are released by mast 
cells, dendritic cells, macrophages, epithelial cells, and tumor cells. Exosomes, released from 
mast cells exposed to oxidative stress, have the ability to communicate a protective signal to 
receptor cells exposed to oxidative stress to reduce cell death. Exosomes can influence the 
response of other cells to oxidative stress by providing resistance to oxidative stress to recipi-
ent cells and decreasing the loss of cell viability. The exosomal transfer of RNA is involved 
in cell-to-cell communication and influences the response of the recipient cells to an external 
stress stimulus. The mRNA content of the exosomes produced under oxidative stress differs 
both from the mRNA in the donor cell and in the exosomes produced by cells grown under 
normal conditions. [39]. Exosomes produced by cells exposed to oxidative stress have the abil-
ity to induce tolerance in other cells. This effect is associated with the change in the content 
of exosomal mRNA that is attenuated by the reduced activity of the RNA by exposure to 
ultraviolet light. This shows, for the first time, that exosomal RNA transfer can change the 
biological function of a recipient cell [40]. The encapsulation of biologically active ingredients 
of regeneration in carriers of nonliving exosomes offers advantages in the processing, manu-
facturing, and regulation of MSC-based therapies [41].
Exosomes and ExMVs derived from MSCs influence tissue responses to lesions, infections, 
and diseases, and the exosomes of MSCs are not static, since they are the product of origin 
of MSCs, and they have actions with intercellular immediate neighbors. The MSCs, through 
paracrine action, activate the endogenous repair pathways, and the horizontal transfer of this 
load induces therapeutic changes; meanwhile, it has been demonstrated that microvesicles/
exosomes derived from MSCs repeat the therapeutic effects of the parental MSCs [42].
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A new generation of drug delivery systems can be mediated by exosomes and ExMVs; 
because they have high administration efficiency and low immunogenicity, new therapies 
can be implemented, and standardization is achieved with isolation techniques, with high 
functional efficiency, solid performance, scalable production, adequate storage, and efficient 
loading methods, which do not damage its molecular integrity and the movement of the 
elements in vivo as novel “nano-vehicles” [43]. The elements derived from cells generate an 
endogenous mechanism for intercellular communication; they are vehicles with the capacity 
to transfer biological information and the potential use can be as means of drug delivery [44].
5. Exosomes as biomarkers and therapeutic targets
All cells in the body secrete ExMVs, a heterogeneous population of bilayer vesicles with mem-
brane that transport and deliver loads of proteins and nucleic acids to the recipient cells, 
allowing cell-cell communication. The exosomes, of endosomal origin, regulate normal and 
pathological processes. Healthy subjects and patients with different diseases release exosomes 
with different RNA and protein contents into the circulation, which can serve as biomarkers 
[45]. Compared to conventional biomarkers in serum or urine samples, exosomal biomarkers 
have greater sensitivity and specificity due to their high stability. They are present in almost 
all body fluids that harbor molecular components, exosomal proteins, and miRNA, and they 
are carriers of genetic information, which can be used for diagnosis. Although most RNAs 
found in exosomes are nucleotide fragments of degraded RNA with a length of <200 nm, some 
full-length RNA may be present. For example, circulating exosomal miRNAs are equivalent 
to those of the cancer cells of origin [45].
The power of nanovesicles as biomarkers depends on the enrichment of the exosomal classifica-
tion markers, which otherwise only represent a very small proportion (<0.01%) of the total pro-
teome of body fluids. The enrichment of the exosomal biomarkers of diagnosis will help in the 
discovery of new biomarkers to provide more precise information related to the origin of each 
exosome. A proteomic analysis and characterization of the plasma exosomes is essential, and 
gel permeation chromatography has been used to purify TNFR1 exosomal-like vesicles from 
the low-density lipoprotein (LDL) fraction. With this multistage purification scheme, it was 
possible to identify the 66 proteins of the circulating healthy exosomes, in the plasma, including 
proteins, both cytosolic and membrane-associated, as extracellular secreted proteins and asso-
ciated with the cells identified with vesicular trafficking. The advantage of this analysis is that 
it allows the separation of different populations of vesicles according to their size. This reduces 
complexity in the identification of proteins in the plasma sample that may contain more than 
1 million different intermixed proteins, and the discovery of peroxisome proliferator-activated 
receptor gamma (PPARγ) as a component of plasma exosomes will allow identifying a new 
pathway for the paracrine transfer of nuclear receptors specific in each pathology [46].
5.1. Exosomal proteins as diagnostic biomarkers
The molecular content of exosomes is the fingerprint of the cell type that released it and 
its current status; most viable cells release extracellular environment, protein secretions of 
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exosomes, and when fused with the plasma membrane, appear in the blood and urine, so 
they are easily accessible, and can be used as biomarkers, for the diagnosis and prognosis of 
malignant tumors and other pathologies [47, 48].
Due to their cellular origin, exosomes express protein markers specific to the endosomal path-
way, such as tetraspanins (CD63, CD9 and CD81), heat shock proteins (Hsp70), proteins of the 
Rab family, Tsg101 and Alix, which are not found in other vesicles of similar size. Their func-
tion is to eliminate damaged or aged cellular molecules, to protect cells from the accumulation 
of waste or drugs, participate in physiological and pathological processes, and have a wide 
variety of clinical applications, ranging from biomarkers to cancer therapy [49]. Proteomic and 
biochemical analysis of the purified exosomes revealed that the bilayer membrane of phos-
pholipids is embedded with various proteins and lipids originating in the parental cells. These 
can serve as surface markers for the characterization and differentiation of exosomes from 
other types of microvesicles [50]. Exosomes contain various proteins, which express specific 
cellular functions, so they can serve as biomarkers for the diagnosis of liver, kidney, and can-
cer diseases [51]. Proteins in urinary exosomes are easily available through nontoxic means, 
are invasive, and are useful in diagnosis, especially for diseases of the urinary tract [52].
5.2. Exosomal nucleic acids as diagnostic biomarkers
Exosomes contain exosomal RNAs, especially miRNAs that function as diagnostic biomarkers, 
are protected from RNase-dependent degradation, are detected in circulating plasma, and serve 
for the diagnosis of ovarian cancer [53, 54]. Nanostructure analysis and study of the transcrip-
tome of exosomes that transport RNA are diagnostic and found in breast milk, saliva, blood, 
urine, malignant ascites, amniotic fluid, bronchoalveolar secretion, and synovial fluid [55, 56].
Urinary extracellular vesicles (uEV) are released in the nephron of the kidney and urinary 
tract. Specific proteomic and transcriptomic markers provide information on the cell of origin 
and are a reservoir for the discovery of biomarkers in kidney diseases. The uEV are a new 
means of cell signaling, renal tubular cells, and can provide exosomal markers not detectable 
in urine. Renal biopsy is an invasive technique with complications such as infection and hem-
orrhage. The analysis of proteomic and transcriptomic changes of uEV in different disease 
states as a biomarker can be a noninvasive alternative to biopsy [57].
In conclusion, the most important biomedical utility of exosomes is their application as biomark-
ers in clinical diagnosis. Compared with those detected in conventional samples, such as serum 
or urine, exosomal biomarkers provide comparable or superior sensitivity and specificity, attrib-
uted to their excellent stability, and the exosomal biomarkers of biofluids can be easily obtained. 
Recent technical advances in the isolation of exosomes will make diagnostics more beneficial.
6. Stem cell therapeutics; exosomes as biomarkers in cardiovascular 
diseases
The intercellular communication between cardiac, vascular, SCs, and progenitor cells with 
differentiated cardiovascular cells is a complex process, with a diversity of mechanisms in 
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cardiovascular disease and therapeutics. The EVs are produced through different pathways 
and are released and absorbed by most cells including cardiac, vascular, and progenitor stem 
cells [58].
The conventional treatment in obstructive coronary disease is percutaneous coronary revas-
cularization, angioplasty, stent placement, or coronary revascularization graft. In patients 
where there was no improvement or these treatments were not indicated, it is necessary to 
limit the damage produced by MI, to restore blood flow, and supply blood to the ischemic 
region. Microcirculation is a therapeutic target for the treatment of ischemic disease. Several 
preclinical studies show that CD34+ cells can stimulate neovascularization in ischemic tissue 
by increasing capillary circulation and improving acute and chronic myocardial ischemia [59]. 
A double-blind study showed lower rates of amputation in patients with critical ischemia of 
the lower limb with the administration of CD34+ cells [60]. Other studies mention that trans-
plantation of CD34+ cells into ischemic myocardium after MI is better than neovascularization 
with mononuclear cells [61].
Cardiovascular diseases (CVD) have a high prevalence, morbidity, and mortality. The identi-
fication of biomarkers with high sensitivity and specificity can evaluate the prognosis of CVD, 
optimize personalized treatment, and reduce mortality. Biomarkers based on exosomes may 
reflect the stage and progression of coronary artery obstruction, heart failure, cerebrovascular 
accidents, arterial hypertension, cardiac arrhythmia, cardiomyopathy, valvular heart disease, 
and pulmonary arterial hypertension. On the other hand, exosomes as immunomodulators 
can be used in cardiac ischemia, pulmonary hypertension and many other diseases, including 
cancer, and also be used as a biomarker of the disease [62, 63]. Some exosomes can inhibit 
cell apoptosis and increase cell proliferation, contain specific surface proteins and the like, 
such as CD9, CD63, CD81, and proteins can transfect cardiomyocytes, endothelial cells, SC 
fibroblasts, and smooth muscle cells, and induce beneficial cellular changes. The release of 
exosomes from the cell is mainly regulated by Rab GTPase (Rab27a/b and Rab35). After a MI, 
the exosomes work in local and systemic microcommunications, in the exosomal transport 
of miRNA, and in the contribution of signals for cardiac repair, the myocardium can secrete 
exosomes, especially those that emerge in the border area of MI, so control of the quality and 
quantity of exosomes can serve as biomarkers in the diagnosis and prognosis of MI and as a 
new therapeutic objective to regulate cardiac remodeling [64].
The EVs secreted by the cardiac progenitor cells (CPC) can improve the cardiac function 
after the lesion by the content of exosomes with angiogenic factors that generate the ischemic 
tissue repair and are cardioprotective agents; the exosomes are the active components of 
the CD34+ of the BM. Experimentally, exosomes secreted by MSCs and CPCs have been 
shown to decrease tissue damage and facilitate ventricular remodeling in animal models of 
myocardial ischemia and reperfusion injury. The EVs are the active paracrine component of 
the CPCs [65].
In a study of stability, the exosomes of adult cardiac myocytes were shown to release heat 
shock protein (HSP) 60 in exosomes. When this protein is not in the exosomes, apoptosis is 
generated through the activation of the Toll-like receptor 4 and the release of Hsp60 would 
damage the surrounding cardiac myocytes. On the other hand, fever and a change in the pH 
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or ethanol consumption increase the permeability of the exosomes, and different inducers 
of exosomes modify the content of the exosomal protein. The production of reactive oxygen 
species (ROS) is an underlying mechanism of increased production of exosomes and etha-
nol at “physiological” concentrations would trigger the release of exosomes. This work, as 
determined by Western blot analysis and mass spectrometry, mentions that exosomes retain 
their protein load in different physiological/pathological conditions; the protein content of 
the exosomes’ cardiac etiologies differed from other types of exosomes due to their content 
of cytosolic, sarcomeric, and mitochondrial proteins. Ethanol did not affect the stability of the 
exosomes but increased the production of exosomes in cardiac myocytes; exosomes derived 
from ethanol and hypoxia/reoxygenation had a different protein content. Finally, inhibition 
of ROS reduced the production of exosomes [66].
Through circulating blood, circulating exosomes can reach distant tissues, allow direct com-
munication with target cells, and regulate intracellular signals. Circulating exosomes and 
their exosomal charges participate in the hypertrophy of cardiomyocytes, apoptosis, and 
angiogenesis. Circulating exosomes enriched with various types of biological molecules can 
be modified in number and in loads of exosomes in cardiac lesions, such as MI, reperfusion 
injury, myocardial ischemia, atherosclerosis, hypertension, and cardiomyopathy due to sep-
sis, and can influence the function of the cardiomyocytes and contribute to the pathogenesis 
of CVD. A therapeutic strategy based on exosomes can be used to decrease myocardial injury 
and induce cardiac regeneration [67].
The CD34+ cells are a structural component in the formation of neovasculature in ischemic 
tissue, and secrete paracrine factors that stimulate the formation of new vessels, an element 
of proangiogenic paracrine activity associated with CD34+ cells secreted by exosomes, with a 
potent angiogenic paracrine activity both in vitro and in vivo. Exosomes stimulate mechanisms 
mediated by genetic receptors by transferring proteins, RNA, or microRNA directly to the 
cytoplasm of target cells [68].
All types of cardiac cells are able to secrete ExMVs, which are captured by the recipient cells 
and can alter gene expression or activate cascades of intracellular signals. A possible therapeu-
tic intervention to reduce the ischemia/reperfusion injury (I/R) is the pre or post-conditioning, 
which allows the activation of the salvage recovery pathway by reperfusion salvage kinase 
(RISK), where transcription factors such as factor 1α-induced hypoxia (HIF-1α), mediators 
such as heat shock protein 70 kDa (Hsp70) and inducible nitric oxide synthase (iNOS), dem-
onstrated in an in vitro preconditioning model, which does not influence the secretion of EV 
and its morphology, but it has an effect on EV size and particularly on its charge. EVs derived 
from fibroblasts enhanced cell migration and the effect was improved by means of in vitro 
preconditioning. An experimental model of in vitro preconditioning of cardiac cells concluded 
that it does not influence the concentration of ExMVs, but regulates their load and affects 
migration [69].
In conclusion, cardiac cells, such as cardiomyocytes, endothelial cells, and fibroblasts, release 
exosomes that modulate cellular functions. The exosomes released by CPCs are cardioprotec-
tive and improve cardiac function after MI, compared to that achieved by progenitor cells, 
and they have antiapoptotic, proangiogenic functions.
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7. Cancer stem cells (CSC); exosomes
Malignant tumors arise from a small subset of cancer cells, have tumor heterogeneity, and 
small populations of cells with characteristics equivalent to SCs. These cells, called cancer 
stem cells (CSC) or cancer-initiating cells (CIC), have been identified in many malignancies 
and are thought to form the tumor clonogenic nucleus. The CSCs share many characteristics 
of ES and show activation of one or more signal transduction pathways, which are involved in 
tissue homeostasis and development, including Notch, Hedgehog (Hh), and Wnt pathways. 
Notch signaling, similar to the Wnt and Hh pathways, is a pathway for determining the fate 
of the evolutionarily conserved primordial cell, with great relevance in the biology of cancer, 
from CSC to angiogenesis and tumor immunity. The CSCs generally have slow growth rates 
and are resistant to chemotherapy and/or radiation therapy. The new treatment strategies 
seek to control the replication, survival, and differentiation of the CSCs [70]. These cells origi-
nate from a more differentiated cancer cell, with self-renewing properties, probably as a result 
of epithelial to mesenchymal transmission [71].
The most important and useful property of the CSC is that of self-renewal and characteristic 
differentiation, which is considered as a one-way specialization process as the cells develop 
the functions of their final destination and lose their immature characteristics, such as self-
renewal. This property shows parallels between SCs and cancer cells. The tumors originate by 
the transformation of normal SCs by means of similar signaling routes, to which they regulate 
self-renewal, both of SCs and CSCs; the latter include the undefined potential of self-renewal 
that starts tumorigenesis. Otherwise, CSCs could be derived from a SC of normal tissue that 
undergoes a transformation as a result of oncogenic somatic mutations, due to the influence 
of extrinsic microenvironmental factors [72].
The CSCs are associated with tumor onset, metastasis, progression, invasion, recurrence, and 
resistance to therapies, and they play a central role in the biology of cancer cells; they interact 
with their surrounding cells inducing angiogenesis and metastasis. In the tumor microenvi-
ronment, multiple types of cells coexist, including adult SCs, CSCs, and stromal cells, and 
communicate with each other in modulating, tumor progression, functionally release exo-
somes that can be absorbed by CSCs or adult SCs, and modify their phenotype. Recent studies 
show that exosomes participate in interactions between cells within the tumor microenviron-
ment by means of exosomal signals, modulating tumor progression [73].
We take Hannafon’s approach in questions related to the function of the exosomes involved in 
the interaction of CSCs, adult SCs, and the surrounding cells within the tumor microenviron-
ment, which are:
Do CSCs or adult SCs secrete exosomes that affect the function of the stromal cell? Are CSCs 
or adult SCs modified by the exosomes released from CSCs and surrounding stromal cells?
What are the possible molecular mechanisms and the biological consequences of exosome-
mediated interactions between CSCs, adult SCs, and the cells that surround them? [74].
The SCs secrete a large number of exosomes, and in the extracellular environment, they func-
tion as intercommunicators in the tumor microenvironment and actively in tumorigenesis, 
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angiogenesis, and tumor metastasis, and the mechanism of interaction between the cancer 
cells and the tumor cells involves the exchange of biological material through exosomes. On 
the other hand, exosomes induce the formation of the premetastatic niche, which regulates 
tumor metastasis. Mechanisms mediated by exosomes contribute to resistance to antitumor 
therapy. Certain exosomes have an influence on tumors to evade immune surveillance [75].
Exosomes derived from SCs provide information related to the regulation of genes to tar-
get cells, for cell growth and angiogenesis by the modulation of various signaling pathways. 
Exosomes derived from MSCs potentiate the expression of VEGF in tumor cells by activat-
ing the kinase 1/2 pathway regulated by extracellular signal regulated kinases (ERK1/2) that 
promote tumor growth [76].
The ExMVs released by adipose mesenchymal stem cells (ASC) may contribute to angio-
genesis induced by ASCs. In CSC, exosomes derived only from CD105+ CSCs conferred an 
activated angiogenic phenotype to normal human endothelial cells, stimulating their growth 
and vessel formation. A specific source of the ExMVs derived from CSCs contributes to trig-
gering the angiogenic process and metastatic diffusion during tumor progression. The effects 
of exosomes of different types of SCs on angiogenesis are similar to those of exosomes derived 
from SCs in tumor growth [77].
Exosomes released from SCs contribute to tumor metastasis. Several key steps in tumor inva-
sion and metastasis are associated with MSCs, and include the epithelial-mesenchymal transi-
tion and the induction of SC-like properties that allow CSCs to increase their survival capacity 
through circulation [78].
Recently, CSCs have been used in the diagnosis and treatment of cancer. The exosomes 
released from prostate and breast cancers have specific biomolecular characteristics, includ-
ing the expression of several exosomal markers such as CD9, CD63, CD81, ALIX, and TSG101. 
In addition, the exosomes derived from GC-MSC contain miR-221, which is a new biomarker 
for the diagnosis of several tumors. The finding of tumor biomarkers is a new diagnostic tool. 
The release of exosome cells provides valuable detailed molecular information about the cell 
of origin and the tumor characteristics, can be isolated from easily accessible body fluids, and 
can provide specific information for the predictive diagnosis of multiple tumors [79].
8. Future conclusions and addresses
Due to its complexity, the research and application of cell therapy with cells and cellular 
products should be considered with a multidisciplinary and translational approach and rep-
resents a great therapeutic potential for refractory diseases to conventional treatments such 
as noncommunicable chronic diseases: diabetes, cardiovascular ischemic diseases, cerebro-
vascular or renal diseases, degenerative diseases such as cancer, neurodegenerative such as 
Alzheimer’s disease, multiple sclerosis, and aging.
Thus, cell therapy with MSCs emerges as a promising therapeutic tool, the main thera-
peutic objective of which is healing through trans-differentiation to repair and replace 
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damaged cells and generate new healthy cells. The rapid progress in MSC research and 
the primary function in cellular niches under normal and pathological physiological con-
ditions and the management of cellular intercommunication of the microenvironment 
through the paracrine secretion and their biological products are being incorporated into 
clinical practice.
The initial paradigm of cellular therapy for tissue and organ repair and regeneration has been 
modified, with new knowledge from experimental, preclinical, and clinical studies related 
to the mechanism of action of MSCs both in vivo and in vitro, which have demonstrated to 
be processes fundamentally of paracrine action, by means of the generation of exosomes, 
microvesicles, and the horizontal transfer of proteins, mRNA, and microRNA.
Recently, a group of secreted vesicles, the “exosome”, has been identified as the main media-
tor of the therapeutic efficacy of MSC. The ExMV participate in intercellular, local, and remote 
communication, which are translated into pleiotropic actions and generate a therapeutic 
potential by transferring biologically active molecules and which can be used as new bio-
markers and potential regulators of inflammation and immune response to detect immune 
rejections. Exosome/microvesicle therapy derived from MSCs has potential advantages. First, 
it prevents the transfer of cells that may have mutated or damaged DNA. Second, the vesi-
cles are small and easily circulated, while the MSCs are too large to easily circulate through 
the capillaries and many do not even reach the first capillary bed. Third, the dose of MSC 
decreases rapidly after transplantation, but the administration of the biological products of 
the cells allows higher therapeutic “doses”. The disadvantage of using vesicles derived from 
MSCs is that they are static and cannot occur more when they are transplanted. The thera-
peutic efficacy of MSCs is based on their ability to respond in the microenvironment of the 
lesion, whereas the isolated exosomes are not expected to do so. The opportunity to exploit 
the potential therapy of MSCs and their products opens new scenarios for the identification 
of new molecules for the repair and regeneration of organs and tissues through proteome 
analysis of the secretome.
In the short term, the exosomes derived from MSCs will progress to clinical studies, and 
their usefulness and effectiveness will depend on establishing a series of critical param-
eters such as standardizing reproducible production methods for the manufacture of exo-
somes/microvesicles with precisely defined content, standardizing storage methods that 
maintain their potency, and evaluating therapeutic efficacy in controlled clinical trials, of 
appropriate power, designed with written criteria and with solid research foundations 
to generate scientific results that allow the translation of basic knowledge to create new 
regenerative therapies.
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